Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cholesterol sulfate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Cholesterol sulfate. Displaying page 1 of 1.
    EudraCT Number: 2020-003770-50 Sponsor Protocol Number: 20200403 Start Date*: 2021-10-13
    Sponsor Name:Všeobecná fakultní nemocnice v Praze
    Full Title: An Open-Label, Single/Multiple Ascending Dose Study to Assess the Pharmacokinetics, Efficacy, Safety and Tolerability of Inhalation Delivery of Hydroxychloroquine Sulfate (HCQ) in Healthy Volunteer...
    Medical condition: Healthy volunteers and patients with COVID - 19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084510 Coronavirus infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002043-16 Sponsor Protocol Number: GS-EU-164-0206 Start Date*: 2008-09-02
    Sponsor Name:Gilead Sciences Europe Ltd.
    Full Title: Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi...
    Medical condition: Sujetos adultos, infectados con el VIH-1, que están siendo tratados con un régimen TARGA estable de Kivexa + Kaletra, con colesterol elevado. Adult HIV-1 infected subjects on a stable HAART regime...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003354-28 Sponsor Protocol Number: GS-UK-177-0109 Start Date*: 2008-02-19
    Sponsor Name:Gilead Sciences Limited
    Full Title: A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Onc...
    Medical condition: Adult, HIV-1 infected, tenofovir DF- and emtricitabine-naive subjects on a stable HAART regimen of Kivexa (abacavir/lamivudine) and efavirenz, with raised total fasting cholesterol
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002281-70 Sponsor Protocol Number: 2014-002281-70 Start Date*: 2015-02-19
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted daru...
    Medical condition: tratement HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017032-41 Sponsor Protocol Number: AI424-402 Start Date*: 2011-08-01
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and...
    Medical condition: HIV-1 infected subjects who are virologically suppressed on a regimen of 2 NRTIs plus any 3rd agent, but experience safety and/or tolerability issues to this regimen.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000484-13 Sponsor Protocol Number: AG-348-C-003 Start Date*: 2015-07-10
    Sponsor Name:Agios Pharmaceuticals Inc
    Full Title: A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001060-21 Sponsor Protocol Number: 374/11 Start Date*: 2011-10-17
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Safety and efficacy of switching a stable combined antiretroviral therapeutic regimen to atazanavir with ritonavir plus lamivudine in treatment experienced HIV positive patients with full and stabl...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000586-20 Sponsor Protocol Number: MK-8591A-017 Start Date*: 2020-03-04
    Sponsor Name:Merck Sharp & Dohme LLC.
    Full Title: A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretr...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000469-62 Sponsor Protocol Number: 2017-000469-62 Start Date*: 2017-07-24
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients
    Medical condition: HIV-1 infected solid organ transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10068341 HIV-1 infection LLT
    20.0 10022891 - Investigations 10057925 Transplant evaluation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024010-61 Sponsor Protocol Number: DRO/IV-ART-01 Start Date*: 2011-11-09
    Sponsor Name:BIOIBERICA, S.A.
    Full Title: NON-INFERIORITY CLINICAL TRIAL ON THE EFFICACY AND SAFETY OF CHONDROITIN SULFATE AND GLUCOSAMINE HYDROCHLORIDE IN COMBINATION VERSUS CELECOXIB IN PATIENTS WITH KNEE OSTEOARTHRITIS
    Medical condition: KNEE OSTEOARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003416 Arthrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000099-27 Sponsor Protocol Number: HEAT01 Start Date*: 2017-04-26
    Sponsor Name:The Department of Urology
    Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial
    Medical condition: Metastisc castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006184-19 Sponsor Protocol Number: SPI-62-CL-2001 Start Date*: 2022-06-22
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome
    Medical condition: Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10014698 - Endocrine disorders 10035109 Pituitary-dependent Cushing's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000301-87 Sponsor Protocol Number: RP-3500-01 Start Date*: 2020-12-22
    Sponsor Name:Repare Therapeutics
    Full Title: Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib in Advanced Solid Tumors with ATR inhibitor ...
    Medical condition: Advanced/recurrent solid tumors which have ATRi sensitizing biomarkers,
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 07:14:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA